Semax UK - Research Peptides UK Evidence and Testing Guide
Semax UK: Laboratory Evidence, Peptide Identity, Testing and UK Regulation
Semax is a synthetic seven-residue peptide built from the ACTH(4-7) fragment and the Pro-Gly-Pro sequence. Most of the accessible evidence concerns cell systems, biochemical experiments and animal models. This guide keeps those findings within their proper preclinical setting and does not present Semax as suitable for human or veterinary use.
Direct Answer
Semax is the synthetic heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro, commonly abbreviated MEHFPGP. It combines amino acids corresponding to ACTH residues 4 to 7 with a C-terminal Pro-Gly-Pro tripeptide. The molecule is frequently described as ACTH(4-7)PGP.
Published laboratory research has examined gene expression, neurotrophin-related signalling, peptide binding, metal-ion coordination, peptidase interactions and molecular responses in experimental ischaemia models. The evidence base is dominated by rat tissue, rodent models, cultured cells and biochemical systems. These findings do not establish effects, safety or suitability outside those research settings.
GOV.UK states that the MHRA considers Semax a medicine rather than a food item and that it may be sold or supplied in Great Britain or the UK only where a marketing authorisation has previously been granted. No current UK marketing authorisation was identified for this article.
Key Points
What Is Semax?
Semax is a synthetic linear heptapeptide. The first four residues correspond to the ACTH(4-7) fragment, while the final Pro-Gly-Pro sequence is a naturally occurring proline-rich tripeptide motif.
The design is intended to preserve the short ACTH-derived regulatory sequence while extending peptide persistence through the C-terminal PGP segment. Semax does not contain the full adrenocorticotropic hormone sequence.
The compound should not be confused with 4-10 Semax records that may describe a different seven-residue ACTH-derived sequence in chemical databases. Accurate sequence declaration is therefore essential.
Semax Naming and Sequence Accuracy
Search results and supplier documents do not always distinguish the same chemical forms.
| Name or notation | Meaning | Why it matters |
|---|---|---|
| Semax | Common name for Met-Glu-His-Phe-Pro-Gly-Pro | The name alone should still be supported by a declared sequence |
| ACTH(4-7)PGP | ACTH residues 4 to 7 followed by Pro-Gly-Pro | Shows how the molecule was designed |
| MEHFPGP | One-letter representation of the seven residues | Useful for checking sequence consistency |
| Semax acetate | Peptide supplied with acetate counterions | Counterion content affects mass and assay interpretation |
| Semax TFA salt | Material associated with trifluoroacetate from synthesis or purification | Residual TFA changes total material composition |
| N-acetyl Semax | N-terminally acetylated derivative | Not chemically identical to unmodified Semax |
| N-acetyl Semax amidate | Derivative with terminal modifications | Requires separate identity and evidence assessment |
Research History
The published laboratory record developed through peptide chemistry, gene-expression work and experimental neuroscience models.
Peptide Design
Researchers developed short ACTH-derived sequences and proline-rich derivatives for experimental study.
Glial Cell Work
In vitro experiments measured NGF and BDNF messenger RNA after Semax exposure in rat-derived glial cells.
Binding and Gene Expression
Rat-brain studies examined tissue distribution, binding and neurotrophin-related expression.
Genome-Wide Analysis
Transcriptomic studies investigated vascular, immune and signalling genes in rat focal-ischaemia models.
Proteomics and Chemistry
Further work assessed brain protein profiles, metal coordination and molecular interactions.
Semax Molecular Profile
Chemical databases may list free peptide and salt-associated records separately.
| Primary sequence | Met-Glu-His-Phe-Pro-Gly-Pro |
|---|---|
| One-letter sequence | MEHFPGP |
| Residue count | Seven |
| Free-peptide formula | C37H51N9O10S |
| Approximate free-peptide molecular weight | 813.9 g/mol |
| PubChem record | CID 9811102 for ACTH(4-7)-Pro-Gly-Pro |
| Structural class | Linear synthetic oligopeptide |
| ACTH relationship | Contains the ACTH(4-7) sequence rather than full ACTH |
| Defined UK marketing authorisation | None identified when checked on 21 July 2026 |
Why Counterions Matter
Peptides made by solid-phase synthesis are often isolated as acetate or trifluoroacetate salts. A mass result for the peptide ion can support molecular identity, but it does not quantify counterions, water, residual solvents or net peptide content.
A vial’s gross powder mass therefore cannot be treated automatically as pure Semax mass. A well-designed assay should state whether quantity is reported as free-peptide equivalent, salt form or total material.
Interactive Semax Evidence Explorer
Select an evidence level to see what it can establish and what it cannot.
Chemistry
Sequence, mass, purity, counterion and metal-binding measurements.
In Vitro
Cell-culture and biochemical responses under controlled conditions.
Animal Models
Whole-organism responses in defined experimental systems.
Human Evidence
Not covered as an evidence base in this article.
Analytical chemistry
Chemical studies can establish molecular properties and test-method performance. They cannot establish safety, clinical effectiveness or suitability for personal use.
In Vitro Semax Research
Cell and biochemical systems provide mechanistic clues while remaining far removed from whole-organism outcomes.
BDNF and NGF Messenger RNA
A 2001 study measured changes in BDNF and NGF gene expression in glial cells obtained from the basal forebrain of newborn rats after Semax exposure. The largest reported expression changes occurred at an early time point.
Peptidase Interaction
A study of human-serum enzymes found concentration-dependent inhibition of selected enkephalin-degrading activities in vitro. This is an enzyme-system observation, not evidence of a whole-body or clinical outcome.
Copper and Zinc Binding
University of Catania and Italian National Research Council researchers examined how N-terminal acetylation changed the coordination of copper(II) and zinc(II) by Semax-related molecules.
Protein Aggregation Systems
Later Italian work examined Semax in copper-associated amyloid and membrane models. Such systems are useful for molecular mechanism research but do not reproduce the complexity of a living organism.
What In Vitro Results Cannot Show
A change in messenger RNA, enzyme activity, metal coordination or artificial-membrane behaviour does not establish absorption, tissue exposure, long-term safety or any personal outcome.
Animal-Model Research
Much of the Semax literature uses rat brain tissue or rodent experimental models.
Rat Brain Distribution
A radiolabelled-peptide study followed Semax-derived radioactivity in rat blood and brain after experimental exposure. Distribution studies can help determine whether labelled material or fragments reach sampled tissues, but they do not prove that the intact parent peptide remains active at every site.
Neurotrophin-Related Gene Expression
Rat studies measured Bdnf and Ngf expression in the hippocampus, brainstem, cerebellum and frontal cortex. Responses varied by tissue and time point, showing that a single statement such as “Semax increases BDNF” oversimplifies a region-specific and time-dependent dataset.
Experimental Ischaemia Models
Several research groups used middle cerebral artery occlusion or ischaemia-reperfusion models in rats. They measured gene expression, proteins, inflammatory pathways, vascular markers and tissue responses. These models are designed to study biological mechanisms under controlled injury conditions.
Behavioural Models
Moscow State University researchers have examined Semax in rodent learning, stress and chemically induced impairment models. Behavioural tasks in rodents can generate hypotheses, but translation to other species cannot be assumed.
Transcriptomic and Gene-Expression Research
Transcriptomics measures which genes are more or less actively transcribed under experimental conditions.
A 2014 BMC Genomics study used genome-wide transcriptional analysis in rat brain cortex after focal ischaemia. The authors reported changes involving genes related to immune and vascular systems, calcium signalling and other cellular processes.
A 2017 study examined microRNA-associated regulation in the same broad research context. MicroRNAs can influence the translation of many gene networks, making interpretation complex and highly dependent on tissue, timing and model design.
Transcriptomic differences are not themselves proof of a desirable biological result. Some changes may be adaptive, neutral, compensatory or model-specific. Replication, protein-level confirmation and functional validation are required.
Proteomic Research
Proteomics examines proteins rather than messenger RNA alone.
A 2021 study involving the Institute of Molecular Genetics and Pirogov Russian National Research Medical University measured selected protein-expression changes in a rat cerebral ischaemia-reperfusion model.
The study considered proteins including phosphorylated JNK, phosphorylated CREB, MMP-9 and c-Fos. These molecules participate in stress signalling, transcription and tissue-remodelling pathways.
Protein changes in one rat injury model cannot establish a general effect beyond that model. They are most useful when interpreted alongside experimental controls, histology, imaging and reproducibility across independent laboratories.
Chemical and Metal-Binding Studies
Chemical modifications can alter how a peptide coordinates metal ions and behaves in analytical systems.
University of Catania researchers and Italian National Research Council collaborators compared Semax with an N-terminally acetylated derivative. They reported that acetylation changed copper(II) coordination and the behaviour of the resulting complexes.
This is important for research-product identification because N-acetyl Semax and standard Semax are not interchangeable names. A mass spectrum, retention time and sequence record should match the exact derivative under study.
Metal-binding studies also illustrate why buffer composition, trace-metal contamination and laboratory materials can affect peptide experiments. Reproducibility requires clearly defined reagents and controls.
University Research Context in the UK and Elsewhere
Independent university work helps explain the biological pathways measured in Semax experiments without validating Semax itself.
University College London and King’s College London
UCL and King’s College London researchers used human motor-neuron models to study BDNF signalling and axonal repair. UCL summarised the work by saying:
“BDNF acts like a master conductor in the orchestra of nerve repair.”
This quotation describes BDNF biology in a separate human stem-cell study. It does not demonstrate that Semax reproduces the same process or produces a human outcome.
Semax Coordination Chemistry
Italian university and CNR researchers examined copper and zinc coordination, showing that terminal chemical modification can materially change peptide behaviour.
Rat Proteomic Model
Researchers contributed to a 2021 rat ischaemia-reperfusion study measuring selected brain protein-expression responses.
Rodent Behaviour and Physiology
University-affiliated groups have examined Semax in several rodent behavioural and physiological models.
Gene and Protein Expression
Russian Academy and later Kurchatov Institute teams produced much of the direct Semax transcriptomic and molecular literature.
Semax Evidence at a Glance
The table separates what has been measured from what remains unsupported.
| Research question | Evidence type | What has been measured | What remains unproven |
|---|---|---|---|
| Is the peptide chemically definable? | Sequence databases and analytical chemistry | Seven-residue MEHFPGP sequence and expected mass | Identity of any untested commercial vial |
| Does Semax affect gene expression in cells? | In vitro rat-derived glial cells | Changes in BDNF and NGF messenger RNA under defined conditions | Translation beyond the specific cell system |
| Does Semax change rat-brain gene expression? | Animal transcriptomics | Time-dependent and tissue-specific transcriptional changes | Meaning outside the experimental model |
| Does Semax alter proteins in rat ischaemia models? | Animal proteomics | Selected signalling and remodelling proteins | Generalisation to other species or settings |
| Does Semax bind metal ions? | Coordination chemistry | Copper and zinc interactions influenced by terminal modification | Biological relevance in complex living systems |
| Is N-acetyl Semax identical to Semax? | Chemical comparison | No, terminal acetylation changes molecular properties | Interchangeability of evidence |
| Is a high HPLC percentage enough? | Analytical-quality principles | Relative chromatographic peak area under one method | Identity, amount, counterions, sterility and stability |
| Is Semax an authorised UK product? | Official UK regulatory sources | MHRA considers it a medicine rather than food | No current marketing authorisation identified |
Important Research Limitations
Semax literature is frequently presented online with more certainty than the underlying methods permit.
- Much of the direct evidence comes from a small number of related research groups
- Many studies use rat tissue or rodent injury models
- Gene-expression findings vary by brain region and sampling time
- Messenger RNA changes do not guarantee corresponding protein or functional changes
- Protein markers do not establish an organism-level outcome
- Different Semax salts and derivatives may not be chemically equivalent
- Commercial research material may differ from material used in published experiments
- Product purity does not establish sterility, stability or intended-use suitability
- Independent replication outside the original research network is limited
- This article does not treat human evidence as an established basis for Semax
How Laboratories Can Test Semax
A credible analytical package uses more than one method and states exactly which chemical form was assessed.
High-Resolution Mass Spectrometry
Checks whether observed peptide ions match the expected molecular mass.
Tandem Mass Spectrometry
Provides fragment-ion evidence consistent with the MEHFPGP residue order.
HPLC or UHPLC
Separates detectable components under a defined chromatographic method.
Peptide Assay
Measures net peptide content rather than total powder mass alone.
Acetate or TFA Analysis
Helps explain the difference between peptide-equivalent mass and total material.
Impurity Profiling
Reviews deletion sequences, truncations, oxidation and synthesis residues.
Stability-Indicating Method
Separates intact peptide from degradation products over defined conditions.
Validation and Scope
Assesses specificity, accuracy, precision, range and robustness for the intended test.
Why One Purity Number Is Inadequate
ICH Q2(R2) treats identity, impurity, assay and other measurements as distinct analytical purposes. A method that estimates chromatographic purity is not automatically a validated identity or quantitative-content method.
- A high main-peak area does not identify the peak by itself
- Mass spectrometry does not quantify total peptide without a suitable assay
- Gross vial weight includes counterions, water and other material
- A raw-material certificate may not represent the finished vial
- Laboratory accreditation applies to a defined scope, not every possible peptide test
Semax UK Regulatory Position
Regulatory information checked on 21 July 2026.
MHRA Treats Semax as a Medicine Rather Than Food
GOV.UK guidance states that Semax is considered by the MHRA to be a medicine rather than a food item. The same page states that Semax may be sold or supplied in Great Britain or the UK only where a marketing authorisation has previously been granted.
No current UK marketing authorisation for Semax was identified in the official sources reviewed for this article.
Presentation and Intended Purpose Matter
MHRA borderline guidance explains that classification can take account of explicit and implied claims, pharmacological properties, intended purpose, packaging, websites, social media and customer reviews.
A “Research Use Only” label does not override a wider presentation directed towards personal use. Product-specific legal questions require professional regulatory advice.
Advertising Restrictions
The Human Medicines Regulations restrict advertising medicinal products where the required marketing authorisation, registration or certificate is not in force.
Claims That Exceed the Evidence
The statements below should not be inferred from the laboratory literature.
“BDNF changes prove a personal outcome.”
Cell and rat-brain expression findings do not establish effects in people.
“Animal ischaemia models establish a treatment.”
Experimental injury models answer mechanistic questions and do not create an authorised clinical indication.
“A Russian research history creates UK approval.”
UK marketing authorisation is jurisdiction-specific and was not identified.
“N-acetyl Semax is simply a stronger Semax.”
It is a chemically modified derivative requiring separate identity and evidence assessment.
“99% HPLC means pharmaceutical quality.”
Peak-area purity does not establish identity, quantity, counterions, sterility or stability.
“Research Use Only settles UK legality.”
The MHRA may consider the complete presentation, purpose and pharmacological context.
How to Assess Semax Research Critically
Use these questions when reviewing a paper, supplier document or Research Peptides UK article.
- Was the exact MEHFPGP sequence used?
- Was the material standard Semax or a modified derivative?
- Was the study biochemical, cellular or animal-based?
- Which species, tissue and experimental model were used?
- Was the experiment independently replicated?
- Were researchers blinded to treatment allocation?
- Were appropriate positive and negative controls included?
- Were gene-expression findings confirmed at protein level?
- Were functional outcomes measured separately?
- Were multiple time points and brain regions assessed?
- Did the paper distinguish intact peptide from metabolites?
- Was the peptide’s counterion form declared?
- Does the COA match the exact finished batch?
- Are identity and purity supported by separate methods?
- Is net peptide quantity reported?
- Is the analytical method fit for its intended purpose?
- Does the source turn animal findings into personal claims?
- Is the claimed product authorised for sale or supply in the UK?
Medical and Editorial Review
This final article has been reviewed for medical context, scientific accuracy, evidence presentation, patient-safety language and editorial clarity by the multidisciplinary panel below.
The reviewers and contributors are identified to provide transparent authorship and accountability. Their inclusion does not represent endorsement of any research product, supplier, personal use, treatment claim or commercial statement discussed in this article.
Dr Laura Geige
Medical Director and Senior Aesthetics Practitioner at It’s Me & You Clinic, with a professional background in dentistry, medical aesthetics and cosmetic dermatology.
Read professional profile
Dr Rimas Geiga
Medical doctor with a professional interest in nutritional sciences, dietology, metabolic health and evidence-based preventative care.
Read professional profile
Dr Snieguole Geige
Dentist and medical doctor with experience across healthcare, preventative medicine and patient-centred clinical standards.
Read professional profile
Dr Giedre Narkiene
Medical doctor and board-certified dermatologist with expertise in medical and cosmetic dermatology, skin health and patient safety.
Read professional profile
Dr Veronika Matutyte
Medical doctor with training and professional experience in gerontology and healthcare management across clinical and hospital settings.
Read professional profile
Livija Samušienė
Qualified cosmetologist with a Bachelor of Health Sciences in cosmetology and a professional interest in skin health, acne and evidence-based aesthetic care.
Read professional profileSemax UK Frequently Asked Questions
Laboratory-focused answers about identity, research evidence, testing and UK regulation.
What is Semax?
Semax is the synthetic seven-residue peptide Met-Glu-His-Phe-Pro-Gly-Pro.
What does MEHFPGP mean?
It is the one-letter amino-acid sequence for Met-Glu-His-Phe-Pro-Gly-Pro.
What is ACTH(4-7)PGP?
It describes the ACTH-derived four-residue segment followed by Pro-Gly-Pro.
How many amino acids are in Semax?
Seven.
Is Semax full-length ACTH?
No. It contains only a short ACTH-derived sequence joined to Pro-Gly-Pro.
Is N-acetyl Semax the same molecule?
No. N-terminal acetylation creates a chemically distinct derivative.
What evidence is discussed in this article?
Analytical chemistry, in vitro experiments, biochemical systems and animal-model studies.
Does this guide describe human use?
No. It does not provide human-use, administration, dosing or outcome information.
What have cell studies measured?
Selected experiments have measured neurotrophin-related messenger RNA, enzyme activity and molecular interactions.
What have animal studies measured?
Studies have measured tissue distribution, gene expression, protein markers and responses in experimental models.
Do BDNF changes prove a personal effect?
No. Cell or animal expression findings do not establish outcomes in people.
Why is UCL research mentioned?
It provides independent context on BDNF biology. It is not Semax evidence.
Why is the University of Catania mentioned?
Its researchers studied the coordination chemistry of Semax and an acetylated derivative.
What is the expected molecular weight?
The free peptide has an approximate molecular weight of 813.9 g/mol.
Why can Semax molecular weights differ online?
Some records include acetate, trifluoroacetate or other salt-associated forms.
Does HPLC prove Semax identity?
Not by itself. Identity normally requires an orthogonal method such as mass spectrometry.
Does a 99% result prove net peptide quantity?
No. Relative purity and quantitative content are separate measurements.
What should a Semax COA include?
Exact sequence, chemical form, batch number, identity method, observed mass, chromatogram, purity result, quantitative assay where performed and clear test limitations.
Is Semax a food supplement in the UK?
No. GOV.UK states that the MHRA considers Semax a medicine rather than a food item.
Can Semax be sold or supplied in the UK without authorisation?
GOV.UK states that it may be sold or supplied only where a marketing authorisation has previously been granted.
Was a current UK marketing authorisation identified?
No current UK marketing authorisation was identified in the sources reviewed on 21 July 2026.
Does Research Use Only guarantee compliance?
No. UK classification can consider claims, intended purpose, pharmacological properties and overall presentation.
Key Takeaways
- Semax is the seven-residue peptide MEHFPGP.
- It combines an ACTH(4-7) fragment with Pro-Gly-Pro.
- The accessible evidence base is dominated by in vitro, biochemical and animal research.
- Rat studies have measured gene-expression and protein changes in defined experimental models.
- University of Catania research shows that terminal modification can change metal coordination.
- UCL and King’s research provides BDNF context but does not validate Semax.
- N-acetyl Semax and standard Semax are chemically distinct.
- One HPLC purity percentage cannot establish identity, quantity, counterions or stability.
- GOV.UK states that MHRA considers Semax a medicine rather than food.
- No current UK marketing authorisation was identified.
Relevant It’s Me & You Clinic Resources
Continue with related evidence-led Research Peptides UK articles.
Research Peptides UK
Read the wider guide to peptide identity, COAs, analytical testing and UK regulation.
Browse the Research Peptides UK seriesMOTS-C UK
Compare Semax with a mitochondrial-derived peptide research field.
Read the MOTS-C UK guideGHK-Cu UK
Explore a separate peptide field where metal binding is central to molecular identity.
Read the GHK-Cu UK guideIpamorelin UK
See another example of separating receptor biology from unsupported online claims.
Read the Ipamorelin UK guideReferences
- PubChem. ACTH(4-7)-Pro-Gly-Pro, Semax, CID 9811102. Accessed 21 July 2026. PubChem record
- Shadrina MI, et al. Rapid induction of neurotrophin mRNAs in rat glial cell cultures after Semax exposure. 2001. PubMed record
- Agapova TY, et al. Neurotrophin gene expression in rat brain under the action of Semax. 2007. PubMed record
- Dolotov OV, et al. Semax binding and BDNF protein levels in rat basal forebrain. Journal of Neurochemistry. 2006. PubMed record
- Shevchenko KV, et al. Kinetics of labelled Semax in rat brain and blood. 2006. PubMed record
- Dmitrieva VG, et al. Semax and Pro-Gly-Pro transcription of neurotrophins and receptors in rat ischaemia models. 2010. PubMed record
- Medvedeva EV, et al. Effect of Semax and Pro-Gly-Pro on VEGF-family gene expression in experimental rat focal ischaemia. Journal of Molecular Neuroscience. 2013. PubMed record
- Medvedeva EV, et al. Semax and genes related to immune and vascular systems in rat focal ischaemia. BMC Genomics. 2014. Open-access article
- Medvedeva EV, et al. Semax regulation of expression in experimental rat focal ischaemia. 2017. PubMed record
- Filippenkov IB, et al. Transcriptome-level analysis of ACTH(4-7)PGP in rat cerebral ischaemia-reperfusion. Genes. 2020. PubMed record
- Sudarkina OY, et al. Brain protein-expression profile in a rat cerebral ischaemia-reperfusion model. International Journal of Molecular Sciences. 2021. Open-access article
- Magrì A, et al. Influence of N-terminal acetylation on Semax copper(II) and zinc(II) coordination. Journal of Inorganic Biochemistry. 2016. PubMed record
- Kost NV, et al. Semax and Selank interaction with enkephalin-degrading enzymes in human serum in vitro. 2001. PubMed record
- UCL Faculty of Brain Sciences. Growth-promoting molecule orchestrates repair of damaged nerve fibres. 29 April 2026. UCL research summary
- Blackburn EV. Investigating BDNF/TrkB signalling in neuronal models. UCL doctoral thesis. 2025. UCL Discovery
- Food Standards Agency. Importing food supplements and health foods, Semax section. GOV.UK. GOV.UK guidance
- Medicines and Healthcare products Regulatory Agency. Borderline products: how to tell if your product is a medicine. Updated 2 July 2026. MHRA guidance
- Human Medicines Regulations 2012, Regulation 279. Legislation.gov.uk
- International Council for Harmonisation. ICH Q2(R2), Validation of Analytical Procedures. ICH guideline
- UK Accreditation Service. Laboratory accreditation and ISO/IEC 17025 scope. UKAS guidance
